The ASCO Post Podcast

Latest Episodes:

Research From the 2021 ASH Annual Meeting & Exposition Dec 17, 2021

Show notes

The 2021 ASH Annual Meeting & Exposition took place from December 11-14. This week, we’re highlighting two studies featured as late-breaking abstracts at the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Research From the 2021 San Antonio Breast Cancer Symposium Dec 11, 2021

Show notes

The San Antonio Breast Cancer Symposium was held from December 7 to 10. On this episode, we’ll hear from three authors of high-impact research that was presented during the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Survival in Advanced Melanoma Dec 03, 2021

Show notes

On this episode, we’ll hear about a study that examined the impact of the time of day that a patient with advanced melanoma receives an immune checkpoint inhibitor infusion on overall survival. Then, we’ll hear about two recent approvals from the FDA—one in relapsed or refractory multiple myeloma, and one for identification of ovarian cancer lesions during surgery.

Coverage of stories discussed this week on ascopost.com:

Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Survival in Patients With Metastatic Melanoma

FDA Approves Triplet Therapy for Previously Treated Patients With Relapsed or Refractory Multiple Myeloma

FDA Approves Pafolacianine to Help Identify Ovarian Cancer Lesions

To listen to more podcasts from ASCO, visit asco.org/podcasts.

SITC 2021: New Data in Immunotherapy Nov 19, 2021

Show notes

The Society for Immunotherapy of Cancer (or SITC) held its Annual Meeting from November 10 to November 14. This week, we’ll hear from two researchers who presented data at SITC.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

NCCN 2021 Virtual Congress on Hematologic Malignancies: Round-up Nov 10, 2021

Show notes

The National Comprehensive Cancer Network’s 2021 Virtual Congress on Hematologic Malignancies took place from October 14 to October 16. The meeting focused on updates to the NCCN Guidelines; new, emerging, and novel therapeutic agents; advances in cancer care; and the practical management of patients with hematologic malignancies. This week, we hear from three presenters who participated in the conference.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Prostate Cancer Research From the 2021 ASTRO Annual Meeting Nov 05, 2021

Show notes

This week, we’re reviewing research highlights in prostate cancer that were presented at the 2021 ASTRO Annual Meeting. We’ll hear from three presenting authors on the role of radiotherapy in combination with androgen-deprivation therapy, androgen suppression, and surgery.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

News From the 2021 ASTRO Annual Meeting Oct 29, 2021

Show notes

The 2021 ASTRO Annual Meeting took place in Chicago from October 24 to October 27. This week, we’re hearing from authors of three late-breaking abstracts. The research focuses on the role of radiotherapy in HPV-associated oropharyngeal cancer, as well as in oligoprogressive lung and breast cancers.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Oncology Care in the Ongoing COVID-19 Pandemic: Expert Commentary Oct 22, 2021

Show notes

Recently, Dr. Govind Persad, of the University of Denver Sturm College of Law, wrote an op-ed for The ASCO Post entitled “Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic.”
On this episode of the podcast, Dr. Persad further discusses the challenges that patients with cancer and their physicians face surrounding COVID-19, as well as some possible solutions. As hospitals and providers have coped with those in urgent need of care, the question of how to prioritize cancer treatments has come to the fore.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

FDA Approvals in Breast and Cervical Cancers Oct 15, 2021

Show notes

This week, the FDA approved new indications for two drugs. The first approval was for abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who are at high risk of disease recurrence and who also have a Ki67 score of 20% or higher. The next day, the agency approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Lung Cancer Data From the ESMO Congress 2021 Oct 08, 2021

Show notes

This week, we’re hearing about lung cancer data from the ESMO Congress 2021—specifically, a novel tyrosine kinase inhibitor for HER2 exon 20–mutated non–small cell lung cancer, and a second-line vaccine for HLA-A2–positive disease.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected